119 related articles for article (PubMed ID: 1583349)
1. CA 15.3 as a signal of undetectable breast cancer metastases in a follow-up period of 4 years.
Pizzichetta M; Bogni A; Seregni E; Maffioli L; de Jager E; Costa A; Bombardieri E
Int J Biol Markers; 1992; 7(1):59-60. PubMed ID: 1583349
[No Abstract] [Full Text] [Related]
2. Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29.
Correale M; Abbate I; Gargano G; Catino A; Dragone CD; Musci MD; Serio G; Paradiso A; De Lena M
Int J Biol Markers; 1992; 7(1):43-6. PubMed ID: 1583347
[TBL] [Abstract][Full Text] [Related]
3. CA-125 is not a useful marker in metastatic breast cancer.
Seckl MJ; Rustin GJ; Coombes RC
Br J Cancer; 1992 Nov; 66(5):875-6. PubMed ID: 1419631
[No Abstract] [Full Text] [Related]
4. CA 549: the theorem of Bayes for obtaining cut-off values.
Blasco R; Rodriguez Cortasa MJ; Barbero EM; Colmenarejo A; Munoz Calvo R
Int J Biol Markers; 1992; 7(4):270. PubMed ID: 1491188
[No Abstract] [Full Text] [Related]
5. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients.
Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M
Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185
[No Abstract] [Full Text] [Related]
6. CA-549 serum levels in breast cancer monitoring.
Zamagni C; Martoni A; Cacciari N; Bellanova B; Vecchi F; Pannuti F
Int J Biol Markers; 1992; 7(4):217-21. PubMed ID: 1491176
[TBL] [Abstract][Full Text] [Related]
7. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.
Bombardieri E; Pizzichetta M; Veronesi P; Seregni E; Bogni A; Maffioli L; Jotti GS; Bassetto MA; Zurrida S; Costa A
Eur J Cancer; 1992; 29A(1):144-6. PubMed ID: 1445733
[TBL] [Abstract][Full Text] [Related]
8. Review of clinical studies of CA 27.29 in breast cancer management.
Beveridge RA
Int J Biol Markers; 1999; 14(1):36-9. PubMed ID: 10367248
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of mucinous carcinoma associated antigen (MCA) levels in patients with breast cancer.
Migali E; Ozzola G; Mariotti D; Ghezzi P; Rinaldini M; Magnanini S
Int J Biol Markers; 1992; 7(1):61-4. PubMed ID: 1583350
[No Abstract] [Full Text] [Related]
10. Clinical significance of the new tumor marker MCA in the follow-up of patients with mammary carcinoma.
Müller-Brand J; Mäcke H
Int J Biol Markers; 1993; 8(2):130-2. PubMed ID: 8366296
[TBL] [Abstract][Full Text] [Related]
11. CA 549 as a marker in breast cancer.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
Eur J Cancer; 1992; 28A(4-5):845-50. PubMed ID: 1524905
[TBL] [Abstract][Full Text] [Related]
13. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer.
Safi F; Kohler I; Röttinger E; Suhr P; Beger HG
Int J Biol Markers; 1989; 4(4):207-14. PubMed ID: 2628501
[TBL] [Abstract][Full Text] [Related]
15. Ceruloplasmin level in women with breast disease. Preliminary results.
Ozyilkan O; Baltali E; Ozyilkan E; Tekuzman G; Kars A; Firat D
Acta Oncol; 1992; 31(8):843-6. PubMed ID: 1290632
[TBL] [Abstract][Full Text] [Related]
16. Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management.
Jensen JL; Maclean GD; Suresh MR; Almeida A; Jette D; Lloyd S; Bodnar D; Krantz M; Longenecker BM
Int J Biol Markers; 1991; 6(1):1-6. PubMed ID: 1856511
[TBL] [Abstract][Full Text] [Related]
17. CEA and CA 15-3 in primary and recurrent breast cancer.
O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
[TBL] [Abstract][Full Text] [Related]
18. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR
Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513
[TBL] [Abstract][Full Text] [Related]
19. A profile of serum CA 15-3, carcinoembryonic antigen, alkaline phosphatase, and gamma-glutamyl transferase levels in patients with breast cancer.
Buamah PK; Bent DJ; Bodger WA; Skillen AW
J Surg Oncol; 1993 Jun; 53(2):84-7. PubMed ID: 8099132
[TBL] [Abstract][Full Text] [Related]
20. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.
Locker GJ; Mader RM; Braun J; Sieder AE; Marosi C; Rainer H; Jakesz R; Steger GG
Oncology; 1995; 52(2):140-4. PubMed ID: 7854774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
